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To evaluate an antigen delivery system in which exogenous antigen can target the major histocompatibility complex (MHC)
class I pathway, a single human papillomavirus (HPV) 16 E7 cytotoxic T lymphocyte (CTL) epitope and a single HIV gp160 CTL
epitope were separately fused to the C-terminus of bovine papillomavirus 1 (BPV1) L1 sequence to form hybrid BPV1L1 VLPs.
Mice immunized with these hybrid VLPs mounted strong CTL responses against the relevant target cells in the absence of
any adjuvants. In addition, the CTL responses induced by immunization with BPV1L1/HPV16E7CTL VLPs protected mice
against challenge with E7-transformed tumor cells. Furthermore, a high titer-specific antibody response against BPV1L1
VLPs was also induced, and this antiserum could inhibit papillomavirus-induced agglutination of mouse erythrocytes,
suggesting that the antibody may recognize conformational determinates relevant to virus neutralization. These data
demonstrate that hybrid BPV1L1 VLPs can be used as carriers to target antigenic epitopes to both the MHC class I and class
II pathways, providing a promising strategy for the design of vaccines to prevent virus infection, with the potential to elicit
therapeutic virus-specific CTL responses. © 1998 Academic Press
INTRODUCTION
Papillomaviruses (PV) are small DNA viruses. Certain
types of human papillomaviruses (HPV), such as HPV 16
and 18, are strongly associated with cervical cancer (zur
Hausen, 1991). Generally, viral infections induce both
humoral and cellular immune responses. Induction of
neutralizing antibody by a prophylactic vaccination has
been the aim of efforts to prevent viral infection. How-
ever, a vaccine which aims to prime for CD81 CTL
responses, in the context of MHC class I, is necessary
for the elimination of viruses replicating in cells and of
virus protein-transformed tumor cells (Tindle and Frazer,
1994). The study of immune responses mounted against
papillomavirus infections has been hampered by the lack
of a conventional cell culture system for the virus. It has
been found that PV major capsid protein L1 (alone or
with minor capsid protein L2) can self-assemble into
virus-like particles (VLPs) when expressed in eukaryotic
systems (Kirnbauer et al., 1992; Zhou et al., 1991). Immu-
nization with VLPs leads to production of PV neutralizing
antibodies (Roden et al., 1994; Christensen et al., 1996;
Kirnbauer et al., 1992) with high efficiency. A single im-
munization with 1 ng VLPs without any adjuvants can
protect a rabbit from cottontail rabbit PV (CRPV) infection,
with the protection lasting at least 12 months (Chris-
tensen et al., 1996). Although the role of cell-mediated
immunity in the control of PV infection and PV-related
epithelial dysplasia is not clear, several clinical and ex-
perimental studies indicate that cell-mediated immune
responses influence both susceptibility to and regres-
sion of HPV infections. In patients with decreased cellu-
lar immunity caused by disease such as malignancy,
renal allograft, HIV infection, regression of anogenital
warts correlated with an active cell-mediated immune
response (Coleman et al., 1994; Frazer et al., 1986; Alloub
et al., 1989). PV early proteins E7 and E6 have transform-
ing ability and have been implicated in the tumorigenicity
of HPV: their consistent expression appears necessary
to maintain a neoplastic state (Crook et al., 1989) and in
transgenic mouse systems, expression of these genes
leads to tumor formation (Lambert et al., 1993), suggest-
ing the importance of E7 and E6 in cervical carcinogen-
esis. Murine and human HPV 16 E7 CTL epitopes have
been identified (Ressing et al., 1995; Feltkamp et al.,
1993), and immunization of mice with the CTL epitopes,
including peptide, resulted in the prevention of tumor
growth (Feltkamp et al., 1993; Meneguzzi et al., 1991),
suggesting that the induction of CTLs responses is nec-
essary for the prevention of HPV-related carcinogenesis.
T lymphocytes sense the virus infection of a cell by
recognizing viral peptides that are displayed at the cell
surface in association with MHC class I molecules. MHC
class I-restricted antigen presentation involves a pro-
cessing of endogenous intracellular proteins into short
peptides, predominantly degraded in the cytosol (Gold-
berg and Rock, 1992; Germain and Margulies, 1993).
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These peptides are then transported by a family of trans-
porters associated with antigen processing (TAP1 and
TAP2) into the lumen of the endoplasmic reticulum (ER),
where they bind to newly synthesized MHC class I mol-
ecules (Townsend and Trowsdale, 1993; Braciale et al.,
1987; Germain and Margulies, 1993). Exogenous soluble
proteins are usually unable to target this pathway and fail
to activate CTL responses. Therefore, a number of anti-
gen presentation systems have been developed to de-
liver exogenous antigens into the cytosolic pathway.
Many of these strategies are designed to present the
antigen as a polyvalent particulate structure. Antigen
presented in association with appropriate adjuvants
could efficiently stimulate CTL responses (Tindle et al.,
1995; Schulz et al., 1991; Ke et al., 1995; Zhu et al., 1995),
but most of them are not available for human use. Re-
combinant live vectors have also been shown to induce
CTL responses but their safety is still uncertain (Londono
et al., 1996; Winter et al., 1995; Zhu et al., 1995). Also, a
Ty-VLPs has been developed as a antigen carrier system
in which antigens are genetically fused to the TYA gene
of the yeast retrotransposon Ty. The TYA gene encodes a
particle-forming protein which normally packages the
RNA molecule that is the intermediate in Ty transposition
(Layton et al., 1993; Adams et al., 1987). But this system
demands the carrier protein be neutral in antigenicity as
far as vaccine is concerned. Recently, hybrid VLPs have
emerged as a new antigen delivery system to induce
both CTL responses and antibody production (Tindle et
al., 1994; Schlienger et al., 1992; Clarke et al., 1987;
Jenkins et al., 1990; Muller et al., 1997; Sedlik et al., 1997;
Griffiths et al., 1993; Evans et al., 1989). Immunization
with these hybrid VLPs has been shown to be able to
provide complete protection against virus challenge
(Sedlik et al., 1997).
We have demonstrated previously that the C-terminus
of bovine papillomavirus 1 (BPV) L1 sequence can be
deleted without affecting the ability of L1 to assemble
into VLPs when expressed in insect cells by recombinant
baculovirus (Paintsil et al., 1996). Up to 60 amino acids
can be fused into this region and maintain the protein’s
ability to form VLPs (Muller et al., 1997). In the present
study, we fused two different defined CTL epitopes, HPV
16 E7 CTL epitope (aa 49–57) (Feltkamp et al., 1993) and
HIV IIIB gp 160 p18-I10 (aa 318–327) (Takahashi et al.,
1988) to the C-terminus of BPV 1 L1 sequence, and
expressed the fusions in insect cells by recombinant
baculoviruses. We demonstrated that these recombinant
BPV1 L1 proteins could spontaneously self-assemble
into VLPs with a morphology very similar to the wild-type
L1 VLPs. Immunization of mice with these hybrid VLPs
efficiently stimulated MHC class I-restricted CTL re-
sponses, and neutralizing antibodies against BPV1 L1
VLPs were also induced.
MATERIALS AND METHODS
Mice, cell lines, and peptides
Female C57BL/6J and BALB/c mice, 8–10 weeks old,
were purchased from Animal Resource Center (ARC,
Australia) and kept in a specific pathogen-free room. C2
(HPV 16E7 transfected EL-4 cells) (Tindle et al., 1995) and
EL4 cell lines were maintained in complete RPMI-1640
medium plus 10% fetal bovine serum (FBS, CSL, Austra-
lia). P815 cell line was cultured in complete DMEM me-
dium plus 10% FBS, and all cell lines were passaged
every 3 days. The peptide RAHYNIVTF, corresponding to
an H-2b-restricted CTL epitope of residues 49–57 from
the HPV 16 E7 protein, and the peptide RGPGRAFVTI,
corresponding to an H-2d-restricted CTL epitope of res-
idues 318–327 from the HIVIIIB gp160 protein, were syn-
thesised by Chiron Technologies Pty Ltd (Australia).
Construction of recombinant baculovirus transfer
vectors
Primers 59-CCGGGATCCATGGCGTTGTGGCAACAAG-
GCCAGAAGC-39 and 59-CCGGAATTCTTATTTTCCTATTG-
TAACAAATGCTCTCCCTGGTCCTCTTCCTGCCCCTTG-
CTGTGCTAAAAATCTTCTTCC-39 were designed to fuse
HIV IIIB gp160 P18-I10 CTL epitope (aa 318–327) to the
C-terminus of BPV1 L1 sequence, deleting nucleotides
from 7625 downstream. The primers also allowed inser-
tion of a stop codon, and one flanking BamHI site at the
59 and a flanking EcoRI site at the 39. The primers
59-CCGGAATCCATGGCGTTGTGGCAACAAGGCCA-
GAAGC-39 and 59-CCGGAATTCTTATTTTTTAAAGGT-
TACAATATTGTAATGGGCTCTTCCTGCCCCTTGCTGT-
GCTAAAAATCTTCTTCC-39 were designed to fuse HPV
16 E7 CTL epitope (aa 49–57) to the C-terminus of
BPV1L1 sequence, in which the same part of C-terminus
sequence of BPV1L1 was deleted, and a stop codon and
enzyme sites were added as above. The PCR products
were digested with BamHI and EcoRI, and named
BPV1L1/HIVp18-I10 and BPV1L1/HPV16E7CTL, respec-
tively. These fragments were then inserted into baculo-
virus transfer vector pVL1393 (Pharmingen) at the BamHI
and EcoRI sites and transformed into Escherichia coli
DH a-5 cells. The correct recombinant clones were con-
firmed by the existence of BamHI and EcoRI sites and
also were sequenced by dideoxynucleotide procedures
to determine the orientation and integrity of the inserted
sequences. The recombinants containing either HIV
gp160 p18-I10 CTL epitope or HPV 16 E7 CTL epitope
were named pVLBPV1L1/HIVp18-I10 and pVLBPV1L1/
HPV16E7CTL, respectively. (See Fig. 1)
Production of recombinant baculoviruses
Recombinant baculoviruses were produced according
to Pharmingen’s BaculoGold transfection kit. Briefly, Spo-
doptera frugiperda 9 (Sf9) insect cells were cotrans-
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fected with BaculoGold lineralized DNA and the recom-
binant transfer vectors. Although this procedure
produced nearly 100% recombinant efficiencies, plaque-
purification was used to ensure no blue plaques (wild-
type) could be detected. High-titer (. 108/ml virus parti-
cles) stocks of recombinant baculoviruses AcBPV1L1/
HIVp18-I10 and AcBPV1L1/HPV16E7CTL were then
prepared by two rounds of amplification.
Production and purification of VLPs
The production and purification procedures were de-
scribed in detail previously (Qi et al., 1996). In general,
Sf-9 insect cells were infected either with recombinant
baculovirus AcBPV1L1/HIVp18-I10 or AcBPV1L1/HPV-
16E7CTL at a multiplicity of infection of 10 plaque-form-
ing unit (PFU) per cell, and incubated at 27°C for 72 h.
The cells were centrifuged, washed with PBS once, and
resuspended in an appropriate amount of PBS in the
presence of 2 mM PMSF. The cell suspension was ho-
mogenized with a dounce homogenizer (tight pestle) by
50 strokes on ice and then centrifuged at 3000 rpm for 10
min at 4°C to separate the nuclear fraction. The nuclear
pellet was resuspended in an appropriate resuspension
buffer and sonicated for 45 s in ice. The nuclei suspen-
sion were then loaded onto a 20% sucrose cushion and
centrifuged at 26,000 rpm in Beckman SW-26 rotor at 4°C
for 2 h. The pellets were resuspended with resuspension
buffer and sonicated again for another 45 s. This resus-
pension was then mixed with CsCl and centrifuged at
21°C with Beckman SW 41 rotor for 20 h. A band at the
CsCl density of 1.30 g/ml was collected and dialyzed
extensively against PBS. The samples were then used
for Western immunoblotting and for transmission elec-
tron microscopic analysis.
Western immunoblot analysis
Protein samples were diluted in SDS–PAGE sample
buffer, boiled at 100°C for 10 min, and then electropho-
resed through a 10% SDS–PAGE gel and transferred to
nitrocellulose membrane. The membrane was blocked
with 5% skim milk in PBS and probed with the anti-L1
monoclonal antibody MC15 (Kulski et al., 1997) at a
FIG. 1. Construction of pVLBPV1L1/HPV16E7CTL and pVLBPV1L1/HIVP18-I10 transfer vector. Either HPV16E7 CTL epitope (aa 49–57) or HIVIIIB
gp160 CTL epitope P18-I10 (aa 318–327) was fused to the C-terminus of BPV1L1 sequence at the position of 7625 by PCR, and then the chimeric
fragments were inserted into baculovirus transfer vector pVL1393 at the restriction enzyme sites of BamHI and EcoRI to produce the recombinant
transfer vector. The integrity of inserted CTL epitopes were confirmed by DNA sequence analysis.
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dilution of 1:2000. Bound antibody was detected by in-
cubation of the membrane with horseradish peroxidase-
conjugated sheep anti-mouse antibody (Silenus, Austra-
lia) at a dilution of 1:1000 and visualized using enhanced
chemiluminescence (ECL) (Amersham).
Transmission electron microscopy
CsCl gradient-purified and dialyzed samples were
mounted onto carbon-coated grids, stained with 2% am-
monium molybdate, pH 6.2, and examined with an Hita-
chi H-800 electron microscope.
Antibody production
Groups of 4 BALB/c mice were injected subcutane-
ously with 20 mg hybrid BPV1L1/HIVp18-I10 VLPs or
BPV1L1/HPV16E7CTL VLPs without adjuvant. Following
the priming immunization, the mice were boosted twice
at 2-week intervals with the same doses. 10 days after
the second boost, the mice were test bled. The sera
were used for capture ELISA assay and hemagglutina-
tion assay.
Capture ELISA
A capture enzyme-linked immunosorbent assay (ELISA)
was developed to measure the antibodies against intact
BPV1L1 VLPs. A rabbit anti-BPV1 virion polyclonal antibody,
which specifically recognized BPV1 virus particle’s confor-
mational epitopes (Liu et al., 1997) was used to coat 96-well
Maxisorp ELISA plates (Nunc) and incubated at 4°C over-
night. After blocking with 5% skim milk in PBS, 50 ml of CsCl
gradient-purified BPV1L1 VLPs, diluted in PBS to 10 mg/ml,
were added to each well and incubated at 37°C for 1.5 h.
Sera from mice immunized with BPV1L1/HPV16E7CTL
VLPs or BPV1L1/HIVP18I10 VLPs were tested by using
twofold serial dilution in 5% skim milk in PBS. A monoclonal
antibody which specifically recognized a BPV1 L1VLP con-
formational epitope (5B6) (Roden et al., 1994) was used as
positive control, and preimmunization mouse serum was
used as a negative control. Bound antibody was detected
with horseradish peroxidase-conjugated sheep anti-mouse
immunoglobulin (Silenus, Australia) at a dilution of 1:1000,
followed by incubation with ABTS in the presence of hydro-
gen peroxide. The reaction was stopped with 1% SDS, and
the absorbances read at 414 nm.
Hemagglutination inhibition assay
The method used here was described previously (Ro-
den et al., 1995). Basically, 1 ml of fresh C57BL/6J mouse
blood was taken in the presence of 100 ml heparin (1000
units/ml) and was resuspended with 9 ml of PBS 1 1 mg
BSA/ml and centrifuged at 1000 g at 4°C for 5 min. The
supernatant and the top white layer of cells were aspi-
rated, and the red blood cells (RBC) were resuspended in
10 ml of PBS 1 1 mg BSA/ml and centrifuged at 1000 g
at 4°C for 5 min. This wash procedure was repeated
three times, and the final RBC pellet was diluted to 1% v/v
in PBS 1 1 mg/ml BSA. One hundred microliters of this
RBC suspension was mixed with the same volume of
BPV1L1VLPs and added to a 96-well round-bottom plate,
held at 4°C without disturbance for 3 h, and then photo-
graphed. For the antibody inhibition assay, the sera were
incubated with 4 vol of a 25% v/v suspension of mouse
erythrocytes overnight at 4°C to reduce nonspecific
binding. The antisera then was cleared by centrifugation
at 1000 g at 4°C and was heat inactivated at 56°C for 30
min. Various dilutions of the antibodies were preincu-
bated with BPV1L1VLPs at room temperature for 2 h with
gentle rocking before mixing with mouse RBCs.
Cytotoxic T lymphocyte assay
Eight- to ten-week-old female C57BL/6J or BALB/c
mice were immunized with 20 mg of BPV1L1/
HPV16E7CTL VLPs or BPV1L1/HIVP18I10 VLPs by foot-
pad injection, either with or without (in PBS) adjuvant
(Quil A) (Dalsgaard, 1974). Control mice were immunized
with BPV1 L1 VLP. Four days after immunization, the
draining popliteal and periaortic lymph nodes were har-
vested and placed in complete RPMI 1640 medium on
ice. A single cell suspension was made using nylon
mesh and resuspended in complete RPMI 1640 medium
plus 10% FCS, 20 units/ml recombinant IL-2 (Sigma). The
2-ml cells (3.0 3 106 cells/ml) were added to each well of
24-well plates and incubated at 37°C, 5% CO2 for 4 days.
Target cells used for BPV1L1/HPV16E7 CTL were HPV16
E7-transfected EL-4 (C2) (H-2b) (Tindle et al., 1995) and
EL-4; for BPV1L1/HIVP18I10 CTL assay, HIV-P18-I10 pep-
tide pulsed P815 (H-2d) and P815 were used. Target cells
were pelleted, washed once with serum-free complete
RPMI, and 1 3 107 cells were resuspended in 100 ml
serum-free medium. For the peptide-pulsed target cell
lines, the corresponding peptides were added at a con-
centration of 10 mg/ml. 51Cr (100 mCi) was added to the
cells and incubated at 37°C, 5% CO2 (with loose lid) for
60–90 min, with occasional agitation. The excess 51Cr
was removed using the FCS underlay technique. Effec-
tors and labeled target cells were plated into 96-well
round-bottom plates at various effector/target ratios and
incubated at 37°C, 5% CO2 for 5 h. 100 ml of supernatant
was collected from each well for counting in a gamma
counter. The percentage of specific lysis was calculated
according to the following formula: specific lysis 5 (sam-
ple release 2 spontaneous release)/(maximum re-
lease 2 spontaneous release) 3 100. Maximum release
was generated by adding 100 ml of 10% SDS to 100 ml of
target cells, and spontaneous release was obtained from
100 ml of target cells incubated with 100 ml of medium. All
assays were performed in triplicate wells, and sponta-
neous 51Cr release from the various targets did not
exceed 15%.
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Tumor protection assay
Eight- to ten-week-old female C57BL/6J mice were
immunized with either BPV1L1/HPV16E7CTL VLPs or
BPV1L1 VLPs, or PBS only, by subcutaneous injection,
and boosted once 3 weeks after priming. Two weeks
later, 2 3 106 HPV 16 E7-transfected C2 cells were
injected under the neck scuff, and 10–14 days later, the
mice were sacrificed, and the growing tumors were har-
vested and weighed.
RESULTS
Production of hybrid BPV1L1/HPV16E7CTL and
BPV1L1/HIVP18I10 VLPs
The recombinant baculovirus expression system was
chosen to express BPV1L1 VLPs which contained either
a HPV16E7 or a HIVIIIB gp160 p18-I10 CTL epitope within
the L1 sequence (hybrid VLPs). It has been shown by us
previously that deletion of part of the BPV1L1 C-terminal
sequence did not interfere with L1 self-assembly into
VLPs; in contrast, the yield was increased by an un-
known mechanism (Paintsil et al., 1996). When either the
HPV16E7 or HIVIIIB gp160 p18-I10 CTL epitope was
cloned into the C-terminus of the L1 sequence and ex-
pressed by recombinant baculoviruses in Sf-9 insect
cells, a visible band of around 55-kDa size was detected
by Coomassie blue-staining of density gradient-purified
VLPs separated by SDS–PAGE. The identity of this band
was confirmed by Western immunoblot using L1-specific
MAb 15 (Fig. 3). Compared with wild-type BPV1L1, the
apparent molecular weight of the hybrid BPV1L1s was
lighter as expected. Electron microscopic analysis of
purified BPV1L1/HPV16E7CTL or BPV1L1/HIVP18I10
confirmed a 50-nm particle structure (Fig. 2); no struc-
tural difference was observed when compared with the
wild-type BPV1L1 VLPs.
Antibody responses to hybrid VLPs
To test the ability of hybrid BPV1L1 VLPs to induce
anti-VLP antibody, groups of mice were primed with ei-
ther BPV1L1/HPV16E7CTL or BPV1L1/HIVP18I10 VLPs
without adjuvant, followed by two boosts at 2-week in-
tervals. Anti-BPVL1 VLP antibodies were measured by
capture ELISA, an ELISA capable of maintaining VLPs
structure. Mice produced a strong anti-BPV1L1VLP anti-
body response (Fig. 4). No significant difference of anti-
body titer to L1 VLPs was found between the two
hybrid VLPs. These data demonstrated that the hybrid
BPV1L1 VLPs maintain strong BPV1L1 antigenicity, and
also suggest that different foreign antigens fused to the
FIG. 2. Electron micrography of purified wild-type BPV1L1 VLPs, hybrid BPV1L1/HPV16E7CTL VLPs, and hybrid BPV1L1/HIVP18-I10 VLPs.
Recombinant baculovirus-expressed VLPs were purified as described under Materials and Methods. The bar in BPV1L1/HIV VLPs represents 100 nm,
and magnification of all pictures is the same.
FIG. 3. Western immunoblot detection of BPV1L1 protein. CsCl gra-
dient-purified wild-type BPV1L1 VLPs, hybrid VLPs, and wild-type bac-
ulovirus were separated by SDS–PAGE, blotted onto nitrocellulose
membrane, and probed with MAb MC15 and detected by enhanced
chemiluminescence. Protein markers are shown on the left. The posi-
tion of the L1 protein (55 kDa) is indicated by the arrow on the right.
Lane 1, BPV1L1/HPV16E7CTL; lane 2, BPV1L1/HIVP18-I10; lane 3, wild-
type baculovirus; lane 4, wild-type BPV1L1.
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C-terminus had no significant impact on the integrity of
L1 VLPs. To confirm that immunization produced anti-
body to conformational determinant of VLPs, sera from
immunized animals were examined in a hemagglutina-
tion inhibition assay. All sera from the two groups of mice
were able to prevent BPV1L1VLP-induced agglutination
of mouse erythrocytes (Fig. 5). These results were not
completely consistent with the capture ELISA titer, but
these data suggest that the antisera induced by hybrid
VLPs include potentially virus neutralizing antibody to
conformational epitopes.
In vivo induction of CTL responses by hybrid BPV1L1
VLPs
Hybrid BPV1L1 VLPs carrying either the H-2b CTL
epitope of residues 49–57 from HPV 16 E7 protein, or the
H-2d CTL epitope of residues 318–327 from HIVIIIB gp160
protein, were analyzed for their ability to stimulate in vivo
cytotoxic responses against the inserted epitopes.
C57BL/6J (H-2b) mice were immunized once in their foot
pads with 20 mg of purified BPV1L1/HPV16E7CTL VLPs
plus 10 mg Quil A adjuvant, or with PBS, or with 20 mg of
purified BPV1L1 VLPs in PBS as a control. BALB/c mice
were injected once in their foot pads with 20 mg of
purified BPV1L1/HIVP18I10 VLPs plus 10 mg Quil A, or
with PBS, or with 20 mg of purified BPV1L1VLPs in PBS
as a control. Four days later, draining popliteal and peri-
aortic lymph nodes were harvested, and T lymphocytes
were grown in vitro for 4 days in the presence of IL-2.
Target CTL activity of the effector T cells was tested on
the C2 cell line or HIV P18I10 peptide-pulsed P815 cells
by a standard 51Cr release assay. A strong CTL response
was induced in both hybrid VLP groups (Fig. 6), and no
significant differences were found between the effector
cells primed with hybrid VLPs plus adjuvant and those
cells primed without adjuvant, demonstrating the strong
immunogenicity of these hybrid VLPs in the absence of
any adjuvants. Effector cells from both groups of hybrid
VLP-primed mice did not lyse EL-4 cells, or P815 cells,
confirming the specificity of the CTL responses. Further-
more, in mice immunized with BPVL1 VLP, no CTL re-
sponse was seen against either C2 cells or P18-I10
peptide-pulsed P815 cells. These results therefore dem-
onstrated that these hybrid VLPs can elicit strong anti-
gen-specific CTL responses using the CTL epitopes of
two different proteins in two different MHC class I back-
grounds.
Immunization with hybrid VLPs carrying a CTL
epitope of a tumor antigen can protect mice against
challenge with tumor cells
To test the persistence of the CTL response induced
by hybrid VLPs carrying CTL epitopes, and also
FIG. 4. Mouse anti-BPV1L1 VLP antibody responses induced by
immunization with either purified hybrid BPV1L1/HPV16E7CTL or puri-
fied BPV1L1/HIVP18-I10 VLPs without adjuvant. The specific antibody
was detected by a capture ELISA against intact wild-type BPV1L1 VLPs.
No significant differences were found among the individual mouse in
the group. The graph represents the results from one mouse.
FIG. 5. Mouse anti-hybrid BPV1L1 VLP antibodies inhibit agglutination of mouse erythrocytes by wild-type BPV1L1 VLPs. The assay was performed
as described under Materials and Methods section. All tested sera from VLPs immunised mice inhibited agglutination. The figure represents one
mouse serum from each group. Rabbit anti-BPV1 virus antibody was used as a positive control and preimmune mouse serum as negative control.
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FIG. 6. Specific recognition of HPV16 E7-transformed EL-4 cell line (C2) by CTL bulk cultures generated from hybrid BPV1L1/HPV16E7CTL
VLP-immunized mice and of HIVIIIB P18-I10 peptide-pulsed P815 cells by CTLs from hybrid BPV1L1/HIVP18-I10 VLP-immunized mice. T lymphocytes
were pooled from the draining popliteal and periaortic lymph nodes from: (A) C57BL/6J mice immunized with BPV1L1/HPV16E7CTL VLPs and Quil
A; (B) BPV1L1/HPV16E7CTL VLPs and PBS; (C) C57BL/6J mice immunized with wild-type BPV1L1 VLPs and PBS; (D) BALB/c mice immunized with
BPV1L1/HIVP18-I10 VLPs and Quil A; (E) BPV1L1/HIVP18-I10 VLPs and PBS; (F) BALB/c mice immunized with wild-type BPV1L1 VLPs and PBS. Pooled
T cells were stimulated in vitro with IL-2. After 4 days, the CTL bulk cultures generated were used as effector cells in a standard 51Cr release assay.
Target cells for groups A, B, and C were C2 cells and EL-4 cells; target cells for groups D, E, and F were HIVIIIB gp160 P18-I10 peptide-pulsed P815
cells and P815 cells.
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whether these hybrid VLPs could be used as a thera-
peutic vaccine candidate to treat virus-associated
cancer, a tumor protection assay was performed. It
has been shown previously that HPV 16E7 protein can
function as a tumor antigen eliciting CTL-mediated
tumor rejection (Meneguzzi et al., 1991; Chen et al.,
1991), so we immunized C57BL/6J mice subcutane-
ously with 20 mg purified BPV1L1/HPV16E7CTL VLPs
in PBS, at day 0, and then boosted at day 21. Two
weeks after this, 2 3 106 HPV 16E7-transfected EL-4
cells/mouse were injected under the neck scuff, and
the mice were sacrificed 12 days later to check tumor
growth. As a control, another two groups of mice were
immunized with either BPVL1 VLPs or with PBS only.
As shown in Fig. 7, tumor growth in the hybrid VLP-
primed group was significantly inhibited compared to
the groups immunized with BPV1L1 VLPs or PBS only,
strongly suggesting that the CTL responses induced
by the hybrid VLPs were biologically relevant, and that
this tumor protection required hybrid VLPs carrying
the specific HPV 16 E7 CTL epitope. These data dem-
onstrated that hybrid VLPs could be used as a thera-
peutic vaccine for the control of virus-induced tumors.
DISCUSSION
In this study, we have shown that VLPs can present
antigen to the host immune system in such a way as to
induce CTL specific for epitopes carried by the VLPs, and
also to induce tumor protective immune responses in a
model system in which HPV16E7-specific CTL are both
necessary and sufficient to induce host protective immu-
nity (Fernando et al., 1997). CTL responses have been
shown to play a critical role in the elimination of virus-
infected cells and tumor cells, and so any vaccine
against a virus infection or a tumor must induce a spe-
cific CTL response. Unlike MHC class II-restricted CD41
T cell priming, in which antigen presenting cells (APCs)
pick up antigens in the extracellular compartment and
carry them to the draining lymph nodes where they are
processed and presented to T cells (Rock, 1996; Braciale
et al., 1987; Germain and Margulies, 1993), the classical
MHC class I-restricted antigen presentation pathway re-
quires that the ligand peptide be expressed endog-
enously in the cytosol in which proteins are hydrolysed
by proteasomes or possibly by other proteinases; it has
been suggested that this MHC class I-restricted pathway
is exclusively concerned with monitoring endogenously
synthesized cellular proteins (Rock, 1996), as exogenous
proteins or killed pathogens fail to induce MHC class
I-restricted CTL response in vitro (Braciale et al., 1987). In
general, exogenous antigens are not efficiently pre-
sented to CD81 T cells by MHC class I molecules be-
cause the antigens are unable to gain access to the
cytosolic compartment (Moore et al., 1988), and it has
been suggested that this segregation of exogenous an-
tigens from the MHC class I-restricted pathway is being
used to prevent CTL response from killing self normal
cells that have been exposed to foreign antigens but are
not infected by pathogens (Rock, 1996). Vaccines against
viruses which are based on viral proteins or CTL
epitopes, therefore need to be coupled with certain ad-
juvants to target this pathway inducing effective CTL
responses (Tindle et al., 1995; Schulz et al., 1991; Ke et
al., 1995; Zhu et al., 1995), but Alum, the only adjuvant
available for human use, is not an efficient inducer of
CTLs. Although live vectors have also been used to
induce CTL responses against HPV 16 E7 protein (Zhu et
al., 1995), they are not the best candidates due to their
potential risk.
In the present study, we have demonstrated that PV
virus particles incorporating CTL epitopes efficiently
elicit CTLs and tumor antigen-specific tumor protection
when delivered to mice without adjuvants. Comparing
the immunogenicity of the RAHYNIVTF peptide compris-
ing the minimal H-2b restricted CTL epitope of HPV16E7
delivered without adjuvant with that of E7 chimeric VLPs,
the VLPs were on a molar basis at least 2000 times more
effective at inducing a CTL response in C57BL/6 mice
(data not shown). A number of other carrier systems
FIG. 7. Protection of C57BL/6J mice against a tumor challenge with
HPV16E7-transformed C2 cells after immunization with hybrid BPV1L1/
HPV16E7CTL VLPs without adjuvant. C57BL/6J mice were immunized
subcutaneously with 20 mg/mouse of hybrid BPV1L1/HPV16E7CTL VLPs
without adjuvant, or with wild-type BPV1L1VLPs, or with PBS only, and
boosted after 3 weeks. All mice were challenged subcutaneously with 2 3
106 viable C2 cells 2 weeks after the boost. Tumor masses were measured
at day 12 after challenge. Tumor growth in mice immunized with BPV1L1/
HPV16E7CTL was significantly inhibited compared to mice immunized
with wild-type BPV1L1 VLPs (t 5 5.582, P 5 0.0005 , 0.001) and to mice
immunized with PBS only (t 5 5.176, P 5 0.0008 , 0.001). No significant
difference was found between groups immunized with wild-type BPV1L1
VLPs or PBS (t 5 0.012, P 5 0.99 . 0.05).
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using viral proteins have been used to induce CTL re-
sponses. Hybrid HIV Gag particles induced a strong
anti-V3 loop CTL response (Griffiths et al., 1993), and
chimeric hepatitis B surface antigen particles containing
HIV-1 determinants have also been shown to stimulate
specific CTL responses (Michel et al., 1993). More re-
cently, recombinant parvovirus-like particles harboring a
CTL epitope from lymphocytic choriomeningitis virus
(LCMV) nucleoprotein induced strong CTL responses
against both peptide-coated and virus-infected target
cells and were able to induce complete protection of
mice against a normally lethal LCMV infection (Sedlik et
al., 1997). All this evidence, in conjunction with our re-
sults, strongly suggests that viral proteins that form VLPs
act as an effective antigen delivery system to present
CTL epitopes by an as yet undefined mechanism to the
MHC class I-restricted pathway.
The classical MHC class I-restricted pathway requires
that the newly synthesized MHC class I molecules only
bind to peptides derived from endogenous antigens in
the lumen of ER, and presumably hybrid VLPs follow the
same pathway. It has been shown previously that soluble
proteins administered in liposomes can induce CTL re-
sponses in vivo (Zhou et al., 1992), and hybrid VLPs may
possibly use the same mechanism to gain access to the
cytosol, but evidence from the present study, and also from
recombinant parvovirus-like particles data (Sedlik et al.,
1997), has demonstrated that hybrid VLPs can induce
CTL responses in the absence of any adjuvants. There-
fore it is unlikely that hybrid BPV1L1 VLPs use the same
mechanism which liposomes used by fusing with the cell
lipid membrane. Exogenous proteins have recently been
shown to prime CTL responses in vivo via a novel anti-
gen-presenting pathway. It has been postulated that this
novel pathway is operative in a special subset of anti-
gen-presenting cells (APCs) in vivo (Bevan, 1987), pre-
senting exogenous antigens through a cytosolic pathway
in which antigens in the extracellular fluids are internal-
ized by phagocytosis, macropinocytosis, or other endo-
cytic mechanisms, and the class I-presented peptides
are generated in an extralysosomal compartment and
then transferred from phagosomes or macropinosomes
into the cytosol (Norbury et al., 1995; Kovacsovics
Bankowski and Rock, 1995). Alternatively, particulate an-
tigens are taken up and digested in phagolysosomes
with production of large amounts of peptides that bind
directly to MHC class I molecules, thus bypassing the
classical cytosolic pathway (Lanzavecchia, 1996); these
peptides may be regurgitated and bind the cell surface
class I molecules (Pfeifer et al., 1993) or they may bind
inside the phagosome to class I molecules derived from
the plasma membrane during the process of phagocyto-
sis or specifically targeted from the biosynthetic pathway
(Sugita and Brenner, 1995; De Bruijn et al., 1995). How-
ever, the efficiency of this process is unknown in non-
phagocytic cells in vivo where there is no specific mech-
anism for targeting the protein for entry into the cytosol
(Harding and Pfeifer, 1994). It has been shown previously
that hybrid HIV Gag particles (Griffiths et al., 1993), native
hepatitis B surface antigen particles (Schlienger et al.,
1992), and hybrid parvovirus-like particles (Sedlik et al.,
1997) display high-efficiency induction of MHC class
I-restricted CTL responses in vivo. Previous data dem-
onstrated that the presentation of soluble antigens to
MHC class I is inefficient, but can be boosted by trigger-
ing macropinocytsis (Norbury et al., 1995), or using in-
solubilizing antigen on a particle (Kovacsovics
Bankowski et al., 1993; Falo et al., 1995), or offering inert
particles to be cophagocytosed together with soluble
antigen (Kovacsovics Bankowski et al., 1993). This sug-
gests that the high efficiency at which hybrid BPV1L1
VLPs reach MHC class I pathway is probably due to its
particulate form, although it remains to be established
whether there is a specific mechanism of transfer based
on virus–cell recognition, or whether phagosomes are
simply fragile structures that occasionally burst, thus
releasing a large amount of antigen into the cytosol
(Lanzavecchia, 1996). In addition to being particulate, the
hybrid VLPs also have the advantage of being able to
carry multiple repeats of a CTL epitope (360 copies per
particle). PV infection is restricted to epithelial surfaces.
PVs enter mucosal cells after binding to the a6b4 inte-
grin receptor (Evander et al., 1997) and then enter the
cytosol en route to the cell nucleus (Zhou et al., 1995),
and therefore might be available to the MHC class I
antigen for presentation, although it is unlikely that such
a mechanism of uptake would apply for professional
APCs which lack a6b4 integrin. The exact pathway
which is targeted by hybrid BPV1L1 VLPs is currently
under investigation.
In this study, a high titer antibody response against
wild-type BPV1L1 VLPs was also induced, demonstrating
that the intact antigenicity of the wild-type BPV1L1 VLPs
has been maintained by these hybrid BPV1L1 VLPs.
These antibodies were able to inhibit agglutination of
mouse erythrocytes by wild-type BPV1L1 VLPs, suggest-
ing that they recognize conformational epitopes and
might therefore be neutralizing. Immunization with a pu-
rified antigen on avidly phagocytized particles primes
CTLs which protect animals from subsequent challenge
with tumors expressing the antigen (Falo et al., 1995),
which suggests that hybrid VLPs could be a delivery
system for a combined prophylactic and therapeutic vac-
cine, aiming to prevent both new virus infection and
eradicate existing virus infection.
Both HPV and HIV are sexually transmitted viruses and
are difficult to vaccinate against. The present study has
coupled the papillomavirus L1 VLP and the HIV gp160
CTL epitope, which is in the V3 loop recognized by mice
(Takahashi et al., 1988) and humans (Clerici et al., 1991).
The strong CTL response against this epitope induced
by hybrid BPV1L1 VLPs suggests that it is possible to
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design a vaccine against more than one sexually trans-
mitted virus. The present study has clearly demonstrated
that hybrid PV VLPs can be used as an efficient antigen
delivery system in which both MHC class II and class I
pathways are targeted and provides a novel, safe, and
efficient strategy for virus vaccine design. Since up to 60
amino acids can be fused to the C-terminus of PV L1
sequence, it may be possible to insert more than one
CTL epitope so that a multivalent vaccine could be de-
signed to control several virus infections on several MHC
backgrounds with one immunization.
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